Kyntra Bio Inc (KYNB) (Q3 2026) Earnings Call Highlights: Pivoting to a Pure-Play Rare Disease ...
Kyntra Bio Inc (KYNB) slashed its NovaQuest royalty obligation by $60 million and posted a Q3 2026 profit on a debt restructuring gain, while charting a Q1 2027 Phase III launch for roxadustat in Related Stocks: KYNB ,